Quanterix(US:QTRX)2025-03-17 21:47Financial Performance & Guidance - Quanterix reported Q4 2024 revenue of $35.2 million, an 11% increase compared to $31.5 million in Q4 2023 [25] - The company's full year 2024 revenue reached $137.4 million, a 12% increase from $122.4 million in 2023 [28] - Quanterix anticipates full year 2025 revenue to be between $140 million and $146 million, representing a 2% to 6% growth [36] - The company projects cash usage of $55 million to $65 million for 2025, including $35 million to $45 million for operations and $20 million for the EMISSION acquisition [38] Strategic Initiatives & Acquisitions - Quanterix is expanding its addressable market with the Simoa ONE platform, targeting a $2 billion+ immunology segment [14, 19] - The acquisition of Akoya is expected to significantly expand Quanterix's addressable market to $5 billion [14, 24] - The combined revenue of Quanterix and Akoya is approximately $220 million [24] - Quanterix expects to achieve cash flow breakeven in 2026, which the Akoya merger would expedite [14] Product Development & Innovation - Quanterix launched 20 new assays, including 13 in Neurology and 7 in Immunology [16] - The company is developing the Simoa ONE platform, which is up to 10x more sensitive than current SIMOA technology [19] - Quanterix is building a global infrastructure for Alzheimer's Disease (AD) testing, with a $20 million investment over 2024 and 2025 [14, 22]